Latest Prostate Stories

LINTHICUM, Md., July 25, 2012 /PRNewswire-USNewswire/ -- In response to new data from the Prostate Cancer Intervention vs. Observation Trial (PIVOT) released today in the New England Journal of Medicine, the American Urological Association (AUA) released the following statement, attributable to the AUA Chair of Health Policy David F. Penson, MD, MPH, a prostate cancer expert at Vanderbilt University: "Though on the surface, these new data from PIVOT may imply that radical...

Scientists have identified what may be the Peyton Manning of prostate cancer. It’s a protein that’s essential for the disease to execute its game plan: Grow and spread throughout the body. Like any good quarterback, this protein has command over the entire field; not only does it control cell growth in tumors that are sensitive to hormone therapy, a common treatment for men with advanced disease, but also in tumors that grow resistant to such treatment – a dismal development that...

LAUSANNE, Switzerland, July 24, 2012 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced the treatment of its first patient in a multicentre, open, non-comparative Phase III study to investigate the efficacy, safety, and pharmacokinetics of two subcutaneous (SC) injections of Debio 8206...

(Ivanhoe Newswire) – In a study reported by the New England Journal of Medicine, researchers tried to determine which course of action is more beneficial for men diagnosed with localized prostate cancer through the prostate-specific antigen (PSA) test: radical prostatectomy or observation without surgery? From November 1994 through January 2002, researchers randomly assigned 731 men with localized prostate cancer to radical prostatectomy or observation and followed them through January...

NEW YORK, July 19, 2012 /PRNewswire/ -- Life expectancy is the new metric for PSA testing and prostate cancer, according to the American Society of Clinical Oncology (ASCO). Dr. David Samadi, SMART robotic prostate cancer surgeon, explains how newly released ASCO guidelines put into writing what leading prostate cancer treatment experts have been espousing for years. (Photo: http://photos.prnewswire.com/prnh/20120719/NY43296) The ASCO advises men with a life expectancy of less...

Lawrence LeBlond for redOrbit.com - Your Universe Online Men with early stages of prostate cancer may be better off having their disease monitored rather than going through harsh treatments such as surgery, according to a recent study that found that men in their 60s who had the invasive surgery actually didn’t live significantly longer than those who were only monitored. Results of the research, published Wednesday in the New England Journal of Medicine, suggests that men do not need...

SANTA ROSA, Calif., July 18, 2012 /PRNewswire/ -- Doxorubicin (Dox) is an effective anti-cancer drug, but it's also a very toxic one, causing severe heart and immune damage. The doses needed to impact tumors are not well tolerated by patients; however, researchers may have found an answer through combination therapy. A study published in the journal Cell Biology International has shown that combining Dox with the natural supplement Modified Citrus Pectin (MCP) increases the...

A small, naturally occurring nucleic acid sequence, called a microRNA, known to regulate a number of different cancers, appears to alter the activity of the androgen receptor, which plays a critical role in prostate cancer. Directly targeting microRNA-125b to block androgen receptor activity represents a novel approach for treating castrate-resistant prostate cancer. This promising new strategy for improving the effectiveness of anti-androgenic and other hormonal therapies is described in an...

NEW YORK, July 12, 2012 /PRNewswire/ -- Does prostate cancer surgery lead to bladder surgery as suggested by a newly released Canadian study? Not today, says Dr. David Samadi, one of our nation's top prostate cancer surgeons. Robotic prostate surgery is the minimally invasive removal of a cancerous prostate. Innovation and refinement of technique, such as Dr. Samadi's SMART (Samadi Modified Advanced Robotic Technique) surgery, has dramatically improved surgical outcomes over the...

NEW YORK, July 9, 2012 /PRNewswire/ -- In a first-of-its kind research initiative, radical prostatectomy surgery yielded better survival rates than external beam radiation therapy (EBRT) in the treatment of localized prostate cancer. Dr. David Samadi, world-renowned SMART (Samadi Modified Advanced Robotic Technique) robotic surgeon and prostate cancer treatment expert, talks about this study of more than 1,600 men and the survival benefits of robotic prostate surgery. (Photo:...